Sign in
  1. Home
  2. Companies
  3. ICON Public Limited Company
  4. Financial Ratios
ICON Public Limited Company logo
ICON Public Limited Company ICLR
$ 170.02 0.18%
report update icon

Quarterly report 2026-Q2
added 07-30-2026

ICON Public Limited Company Financial Ratios 2025-2007 | ICLR

Brief overview of ICON Public Limited Company's valuation and returns

Ratios are assessed across five available annual reports in the 2021–2025 interval.

Key multiples at the end of the period are P/E 44.08x (median 44.08x), EV/EBITDA 20.03x (median 20.03x), P/S 1.23x (median 2.33x). Valuation is roughly 47.5% below five-year reference levels. The discount may reflect opportunity or higher perceived risk.

The inverse P/E implies an earnings yield of 2.3%. This is not a dividend yield, but current earnings relative to market price.

Capital efficiency is characterized by ROE 2.5%, ROA 1.4%, ROCE 4.8%. Efficiency ratios are restrained, with capital and assets producing modest returns.

On PEG (4.55x), valuation is stretched relative to growth and requires strong execution.

Cash turnover speed was broadly preserved, with the cycle moving from 62 days to 52.5 days.

Overall assessment

ICON Public Limited Company's discount may reflect genuine profitability issues rather than market inefficiency alone.

Annual Financial Ratios ICON Public Limited Company

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

P/E

 44.1 22.4 46.4 35.7 116.4 32.4 24.3 23.5 21.1 17.5 16.6 20.6 25.7 31.6 50.7 19.1 11.5 26.3 -

P/S

 1.2 2.0 3.2 2.3 3.3 3.9 3.2 2.9 3.4 2.8 2.5 2.4 2.0 1.6 1.2 1.9 1.2 - -

EPS

 2.9 9.0 6.8 6.2 2.3 6.2 6.8 6.0 5.2 4.8 4.1 2.8 1.7 0.9 0.4 1.5 1.6 1.3 -

EV (Enterprise Value)

 16.5 B 23.2 B 33 B 26.5 B 26.4 B 11.5 B 9.81 B 8.17 B 6.6 B 5.28 B 4.83 B 4.02 B 2.99 B 2.09 B 1.4 B 1.41 B 943 M 2 B -76.9 M

EBITDA per Share

 10.5 18.4 18.2 16.7 10.3 8.66 9.19 8.12 7.38 6.58 5.63 4.04 2.69 1.83 1.11 2.11 2.39 2.18 -

EV/EBITDA

 20.0 15.3 22.1 19.4 38.0 22.3 18.3 17.2 15.3 12.8 12.5 13.5 14.6 14.8 15.3 11.2 6.7 15.7 -

PEG

 4.55 1.31 2.39 1.81 11.92 3.48 1.32 0.91 0.64 1.03 0.37 0.31 0.32 0.22 -0.69 - - - -

P/B

 1.1 1.8 2.8 2.1 2.2 5.8 5.5 5.6 5.0 4.9 5.2 3.7 2.9 2.3 1.7 1.8 1.2 - -

P/CF

 9.8 12.9 22.2 32.1 21.5 19.0 22.0 28.2 15.5 21.2 17.3 26.0 13.8 21.2 -76.9 19.1 4.3 25.3 -

ROE %

 2.49 7.83 6.02 5.95 1.90 17.96 23.11 23.82 23.63 27.74 31.39 18.15 11.29 7.34 3.36 13.00 16.48 17.12 -

ROA %

 1.41 4.44 3.29 2.94 0.88 9.67 12.86 13.71 13.11 14.36 13.95 11.28 7.13 4.61 2.21 9.17 10.38 - -

ROCE %

 4.82 10.93 9.82 9.36 4.69 16.94 24.40 21.41 21.41 23.41 24.58 20.43 12.88 8.62 4.04 13.75 18.78 21.80 -

Current Ratio

 2.3 2.3 2.2 2.0 1.9 2.2 2.3 2.4 2.2 1.9 1.5 1.5 1.7 1.6 1.8 - - - -

DSO

 63.4 70.4 79.2 72.5 68.5 81.1 61.3 55.8 82.6 145.0 147.6 133.6 130.9 140.7 135.2 72.4 39.5 - -

DIO

 - - - - - - 0.2 0.5 0.8 - - - - - - 1.3 - - -

DPO

 11.0 9.6 6.8 5.7 6.5 6.9 3.5 3.2 4.8 3.3 2.8 1.1 2.0 4.1 3.2 8.2 4.4 - -

Operating Cycle

 63.4 70.4 79.2 72.5 68.5 81.1 61.5 56.3 83.4 145.0 147.6 133.6 130.9 140.7 135.2 73.6 39.5 - -

Cash Conversion Cycle

 52.5 60.8 72.4 66.8 62.0 74.2 58.1 53.1 78.5 141.7 144.7 132.5 129.0 136.6 132.0 65.4 35.1 - -

All numbers in USD currency

Quarterly Financial Ratios ICON Public Limited Company

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q4 2009-Q4 2008-Q4 2007-Q4

EPS

 0.94 1.37 2.92 -3.67 2.31 1.91 8.96 2.38 1.78 2.27 6.75 1.99 1.41 1.43 - - - 1.37 - -1.17 1.4 1.84 - 1.74 0.91 1.63 - 1.73 1.7 1.64 - 1.55 1.33 1.45 - 1.37 1.2 1.31 - 1.15 1.1 1.14 - 1.05 0.97 0.93 - 0.81 0.66 0.59 - 0.46 0.37 0.32 - 0.3 0.13 0.15 - -0.04 0.22 0.14 1.46 1.61 1.34 -

EBITDA per Share

 4.15 3.45 10.5 0.9 5.08 3.92 18.4 8.18 6.39 5.26 18.2 8.52 6.09 4.43 - - - 3.83 - 1.8 2.46 2.57 - 2.37 1.38 2.3 - 2.32 2.25 2.18 - 2.12 1.83 2.01 - 1.87 1.72 1.84 - 1.64 1.6 1.66 - 1.46 1.37 1.34 - 1.18 0.99 0.88 - 0.73 0.62 0.57 - 0.53 0.36 0.38 - 0.1 0.41 0.33 2.11 2.39 2.18 -

ROE %

 1.24 2.38 2.87 8.21 13.38 13.00 13.37 11.55 11.36 11.14 10.51 5.88 2.87 5.19 3.85 3.85 3.85 8.87 7.48 12.84 17.05 19.46 14.44 20.75 21.54 24.72 18.66 25.00 24.48 24.83 18.62 25.19 25.15 26.91 20.43 26.87 27.01 28.18 20.61 27.74 27.03 25.91 18.45 23.43 20.38 18.42 12.83 16.08 13.91 12.31 8.54 11.01 8.92 7.39 4.91 4.53 3.90 3.94 2.66 15.66 32.52 47.80 13.00 16.48 17.12 -

ROA %

 0.74 1.39 1.67 4.71 7.61 7.38 7.55 6.40 6.21 6.02 5.60 2.96 1.47 2.85 2.18 2.18 2.18 4.98 4.33 7.32 9.52 10.69 7.89 11.34 11.73 13.45 10.22 13.85 13.70 13.84 10.46 14.07 13.84 14.38 10.86 14.23 14.10 14.21 10.36 13.75 13.97 13.96 10.46 13.66 12.93 11.79 8.31 10.35 8.89 7.76 5.33 6.89 5.57 4.63 3.08 2.83 2.55 2.66 1.86 11.03 21.66 0.82 9.17 10.38 - -

ROCE %

 5.68 6.40 6.84 12.96 18.36 18.56 19.28 18.17 18.20 18.18 17.66 9.95 7.06 10.25 7.74 7.74 7.74 13.74 11.63 17.96 21.51 22.96 16.96 24.29 25.05 28.61 21.59 28.92 28.21 28.73 21.56 29.10 29.33 31.79 24.18 31.95 32.54 33.98 24.91 33.18 32.07 30.62 21.61 27.48 24.05 21.86 15.19 19.07 16.47 14.63 10.16 13.06 10.79 9.18 6.19 5.66 4.93 4.90 3.23 16.98 36.28 55.91 13.75 18.78 21.80 -

Current Ratio

 2.3 2.3 2.3 2.3 2.4 2.3 2.3 2.3 2.3 2.2 2.2 2.1 2.1 2.0 - - - 1.9 1.9 1.8 2.3 2.3 2.2 2.3 2.2 2.1 2.3 2.3 2.3 2.2 2.4 2.4 2.3 2.2 2.2 2.2 2.2 2.0 2.1 - - - 1.8 - - - - - - - - - - - - - - - - - - - - - - -

DSO

 64.8 66.1 15.8 60.3 62.3 63.4 15.5 66.7 73.9 79.2 20.5 80.1 80.4 41.6 - - - 65.1 - 49.3 70.0 73.1 - 64.0 73.5 67.2 - 53.9 55.6 56.1 - 54.2 56.8 56.9 - 73.0 74.1 79.9 - 83.7 81.0 87.9 - 86.1 84.5 86.1 - 89.0 87.4 88.8 - 89.4 77.4 78.7 - 73.4 69.7 71.7 - 69.7 70.3 70.2 18.1 9.9 - -

DIO

 - - - - - - - - - - - - - - - - - 0.2 - - - 0.3 - - - 0.3 - - - 0.2 - - - - - - - 0.4 - - - 0.4 - - - 0.3 - - - 0.5 - - - 0.7 - - - 0.8 - - - 1.2 0.3 - - -

DPO

 6.3 8.6 2.3 6.2 6.7 9.2 2.2 6.0 6.0 7.6 1.8 4.2 4.2 2.8 - - - 5.1 - 3.4 6.2 7.2 - 5.7 5.7 4.3 - 3.7 3.7 3.1 - - - - - 3.7 3.9 4.1 - 2.1 2.3 2.5 - 2.2 2.1 1.3 - 3.3 3.5 2.4 - 4.4 4.0 3.4 - 4.3 3.4 3.0 - 3.1 3.9 6.6 2.1 1.1 - -

Operating Cycle

 - - - 61.5 - - 15.4 - - - 20.5 - - - - - - 65.3 - 49.3 70.0 73.5 - 64.0 73.5 67.5 - 53.9 55.6 56.3 - 54.2 56.8 56.9 - 73.0 74.1 80.4 - 83.7 81.0 88.2 - 86.1 84.5 86.5 - 89.0 87.4 89.2 - 89.4 77.4 79.4 - 73.4 69.7 72.5 - 69.7 70.3 - - - - -

Cash Conversion Cycle

 - - - 55.2 - - 13.2 - - - 18.7 - - - - - - 60.2 - 45.9 63.8 66.2 - 58.3 67.7 63.2 - 50.2 51.9 53.2 - 54.2 56.8 56.9 - 69.4 70.2 76.3 - 81.6 78.8 85.7 - 83.9 82.4 85.1 - 85.6 83.9 86.8 - 85.0 73.4 76.0 - 69.1 66.3 69.4 - 66.6 66.4 - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company ICON Public Limited Company, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
 		- -8.98 % $ 14.8 K usaUSA
Biomerica Biomerica
BMRA
 		$ 2.14 1.9 % $ 4.92 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
 		$ 1.17 0.88 % $ 6.37 M usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
 		- - $ 10.6 B niderlandNiderland
Centogene N.V. Centogene N.V.
CNTG
 		- -6.23 % $ 30.6 M germanyGermany
Co-Diagnostics Co-Diagnostics
CODX
 		$ 1.21 0.79 % $ 1.61 M usaUSA
Aspira Women's Health Aspira Women's Health
AWH
 		- -6.19 % $ 10.5 M usaUSA
Brainsway Ltd. Brainsway Ltd.
BWAY
 		$ 14.3 0.7 % $ 486 M israelIsrael
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
 		$ 242.76 0.02 % $ 26.9 B usaUSA
Celcuity Celcuity
CELC
 		$ 88.44 3.05 % $ 4.14 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
 		- - $ 562 M britainBritain
Charles River Laboratories International Charles River Laboratories International
CRL
 		$ 291.5 0.16 % $ 14.4 B usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
 		- - $ 9.42 M israelIsrael
Akumin Akumin
AKU
 		- -17.87 % $ 25.9 M canadaCanada
Accelerate Diagnostics Accelerate Diagnostics
AXDX
 		- -61.36 % $ 2.46 M usaUSA
Biocept Biocept
BIOC
 		- -13.05 % $ 7.29 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
 		- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
 		- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
 		- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
 		- 0.12 % $ 80.1 M chinaChina
Chembio Diagnostics Chembio Diagnostics
CEMI
 		- 0.22 % $ 16.8 M usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
 		- - $ 10.7 B usaUSA
DermTech DermTech
DMTK
 		- -11.32 % $ 2.94 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
 		$ 6.77 1.18 % $ 27 M israelIsrael
DexCom DexCom
DXCM
 		$ 90.82 1.71 % $ 35.4 B usaUSA
Heska Corporation Heska Corporation
HSKA
 		- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
 		- -20.0 % $ 1.06 M usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
 		- - $ 2.69 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
 		$ 1 398.58 0.64 % $ 28.8 B schweizSchweiz
Psychemedics Corporation Psychemedics Corporation
PMD
 		- -1.84 % $ 15.3 M usaUSA
Myriad Genetics Myriad Genetics
MYGN
 		$ 3.16 1.92 % $ 293 M usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
 		- -34.28 % $ 263 K israelIsrael
ENDRA Life Sciences ENDRA Life Sciences
NDRA
 		$ 5.01 4.53 % $ 3.94 M usaUSA
NeoGenomics NeoGenomics
NEO
 		$ 18.05 7.31 % $ 2.31 B usaUSA
Syneos Health Syneos Health
SYNH
 		- - $ 4.46 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
 		- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
 		- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
 		- -16.95 % $ 1.54 M usaUSA
National Research Corporation National Research Corporation
NRC
 		$ 21.85 0.27 % $ 489 M usaUSA
T2 Biosystems T2 Biosystems
TTOO
 		- -39.35 % $ 313 K usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
 		$ 3.48 1.11 % $ 113 K usaUSA
PerkinElmer PerkinElmer
PKI
 		- -0.91 % $ 14.7 B usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
 		- - $ 1.49 B usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
 		$ 1.4 0.32 % $ 420 M usaUSA
Quotient Limited Quotient Limited
QTNT
 		- -11.32 % $ 1.1 M schweizSchweiz
Renalytix AI plc Renalytix AI plc
RNLX
 		- 5.66 % $ 22.7 M britainBritain
Interpace Biosciences Interpace Biosciences
IDXG
 		$ 1.45 2.11 % $ 6.41 M usaUSA
IQVIA Holdings IQVIA Holdings
IQV
 		$ 261.75 0.05 % $ 45 B usaUSA
Surmodics Surmodics
SRDX
 		- - $ 608 M usaUSA